3 Key Takeaways
Plain English Summary- 01Core Finding
Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor).
- 02Study Evidence
Tested in a Phase III clinical trial (3,854 patients) at the Phase III stage.
- 03Practical Meaning
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.
What This Means for You
Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial (blood-vessel lining) cells. In two separate real-world cohorts of 4,981 and 3,854 patients with UC, concomitant use of renin-angiotensin system inhibitors (modulators of vascular inflammation) was associated with reduced long-term complications for vedolizumab but not anticytokine therapies. These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.
The Discovery
A barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses. Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor). Validation in a second Phase 3 trial of 576 participants linked PRO-defined vedolizumab trajectories to long-term disease complications. Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial (blood-vessel lining) cells.
How It Works, Simply
This pharmacology research focuses on inflammation. Researchers evaluated it using a phase III clinical trial (3,854 patients) at the Phase III stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor).
- 02Study Evidence
Tested in a Phase III clinical trial (3,854 patients) at the Phase III stage.
- 03Practical Meaning
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.
Biological Mechanism & Study Design
Study Design & Cohort
Phase III clinical trial
Phase III clinical trial (3,854 patients) · Phase III
Biological Pathway & Modality
Inflammation
Intervention: An ulcerative colitis taxonomy defined by individual patient-reported response
Experimental Findings & Endpoints
A barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses.
Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor). Validation in a second Phase 3 trial of 576 participants linked PRO-defined vedolizumab trajectories to long-term disease complications.
Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial cells.
Clinical Translation & Practice Context
Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial cells.
In two separate real-world cohorts of 4,981 and 3,854 patients with UC, concomitant use of renin-angiotensin system inhibitors (modulators of vascular inflammation) was associated with reduced long-term complications for vedolizumab but not anticytokine therapies. These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.
The Bottom Line · Clinical Pearl
“These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.”
Published in Nature Medicine · Current Stage: Phase III